Reduced Intensity Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Hodgkin Lymphoma: Where Do We Stand?
Open Access
- 30 June 2006
- journal article
- review article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 12 (6), 599-602
- https://doi.org/10.1016/j.bbmt.2006.03.013
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative ProtocolTransplantation and Cellular Therapy, 2006
- Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantationThe Lancet, 2005
- Reduced Intensity Allogeneic Stem Cell Transplantation for Hodgkin’s Disease. Outcome Depends Primarily on Disease Status at the Time of Transplantation.Blood, 2004
- HLA-matched related (MRD) or unrelated donor (URD) nonmyeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD)Transplantation and Cellular Therapy, 2004
- An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantationBone Marrow Transplantation, 2003
- Long-Term Results of Blood and Marrow Transplantation for Hodgkin’s LymphomaJournal of Clinical Oncology, 2001
- ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION AS ADOPTIVE IMMUNOTHERAPY: Induction of Graft-Versus-Malignancy as Primary TherapyHematology/Oncology Clinics of North America, 1999
- Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.Journal of Clinical Oncology, 1996
- Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.Journal of Clinical Oncology, 1996
- Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.Journal of Clinical Oncology, 1993